European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials54
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor54
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?49
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial47
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials44
More knowledge about atrial fibrillation, still we need to learn44
Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients43
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure39
Prevention is still the key to success37
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases36
Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials35
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate31
LDL lowering effect of PCSK9 inhibition is reduced in women31
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients28
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c28
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study27
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk23
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry23
Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry23
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials23
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202223
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors22
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-1922
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study20
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity20
Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases20
What's new in pharmacotherapy at ESC Congress 2023?20
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries20
Oral anticoagulants and antiplatelet treatment in different settings19
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?19
Subcutaneous furosemide in heart failure: a systematic review19
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?19
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis18
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study18
Adherence to pharmacological treatment: how can we improve?18
Thromboprophylaxis for COVID-19-related coagulopathy: what next?17
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE217
Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management17
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis17
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure16
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome16
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?16
Fibrates: one more lost paradise in lipid treatment16
Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization15
Targeting lipoprotein(a): Pharmacotherapy in focus15
Estimated impact of guidelines-based initiation of dual antihypertensive therapy on long-term cardiovascular outcomes in 1.1 million individuals15
Lipid treatment15
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on15
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance14
Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery disease14
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics14
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis14
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials14
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease14
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials14
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation13
Corrigendum to: “2019 guidelines for the diagnosis and management of chronic coronary syndromes”: congratulations and tribulations13
Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction13
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain13
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events13
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground12
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?12
Incidence and outcomes of transient new-onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis12
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis12
Re: Shahim et al., 2024 “Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction”12
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis12
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?11
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry11
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient11
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 202111
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective11
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply10
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Reg10
High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation10
PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 202110
Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation10
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk10
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-1910
Letter to the editor in response to Chan et al. 202310
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry9
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis9
Pharmacogenetic testing to broaden patient eligibility for mavacamten9
Proton pump inhibitors: seeking the golden ratio between gastroprotection and cardiovascular risk9
CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?9
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?9
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics9
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr9
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA9
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy9
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study8
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis8
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia8
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study8
0.10580706596375